Roche says it is thoughtful on token use for AI, shelves a drug from Carmot buy

Summary

Roche CEO Thomas Schinecker discussed the company's AI implementation strategy, noting that AI has contributed to a significant increase in new molecules in its pipeline. The company shelved a drug from its Carmot acquisition and outlined a measured approach to token use in AI applications.